NR3C1 and breast cancer: Assurances that this might not be a problem came from preclinical studies in which we found that FFNP uptake in syngeneic murine mammary tumors could be efficiently blocked by coadministration of a blocking dose of the specific PgR ligand, R5020, but not by the specific GR ligand, dexamethasone [84].